NeuroPace Model RNS-300M Model RNS 320 RNS system cortical strips—CL315-10, CL-325-10, CL-335-10 RNS system depth leads—DL-330-3.5, DL-330-10, DL-344-3.5, DL-344-10 Nevro Corporation Senza Omnia IPG—NIPG2500 Surpass paddle leads—LEAD3005-50B and LEAD3005-70B Omnia percutaneous leads—LEAD1058-50B, LEAD1058-70B, LEAD1058-90B LivaNova PLC 100 NCP IPG Sentiva…
Introduction To address the future of neuromodulation, it is first important to recognize that I believe that evolutionary changes in neuromodulation devices do not play a critical role in this future. In the past, the field has identified that changes…
Since the resurgence of neurostimulation technologies in the 1990s, promising advances have been made in this field by altering nervous system function for relief of pain and other symptoms in select patients. Combined with a better understanding of the disease…
Introduction Spinal cord stimulation (SCS), a treatment for chronic intractable pain, was founded on the gate control theory of pain, which proposes that pain transmission is inhibited by activity in sensory afferent fibers, specifically Aβ fibers [ ]. SCS was…
Introduction One of the greatest advantages of neuromodulation therapies, and in contrast to ablative procedures of the past, is that the anatomical and physiological substrate of the therapy may continue to be manipulated long after the implant surgery is accomplished.…
Conflicts of interest Dr. Pilitsis is a consultant for Boston Scientific, Nevro, TerSera, and Abbott and receives grant support from Medtronic, Boston Scientific, Abbott, Nevro, TerSera, GE Global Research, SBIR 1R43NS107076-01A1, NIH 2R01CA166379-06 and NIH U44NS115111. She is medical advisor…
Introduction As neuromodulation therapies become a treatment standard for a variety of disorders including medically refractory Parkinson's disease (PD), essential tremor, dystonia, pain syndromes, epilepsy, psychiatric disorders, and other future indications, more is being learned about the longevity and function…
Disclosures Dr. Pilitsis is a consultant for Boston Scientific, Nevro, TerSera, and Abbott and receives grant support from Medtronic, Boston Scientific, Abbott, Nevro, TerSera, NIH 2R01CA166379-06 and NIH U44NS115111. She is medical advisor for Aim Medical Robotics and Karuna and…
Background Spinal cord stimulation (SCS) has been employed for the treatment of intractable pain most commonly for failed back surgery syndrome and complex regional pain syndromes. It is generally accepted that for successful SCS treatment there is the superposition of…
Introduction Implantable Devices have seen major increases in technology and complexity over the past decade. Fortunately, this has not changed our ability to “Test Drive” our devices. Unlike other interventional or minimally invasive procedures, our patients have the advantage of…